USFDA issues warning letter to Cipla for Goa manufacturing facility

Topics Cipla | USFDA

Drug firm Cipla Ltd on Wednesday said that the US health regulator has issued a warning letter to the company for its manufacturing facility in Goa.

"Further to our earlier communication on the Goa manufacturing facility inspection conducted from September 16-27, 2019 by the United States Food and Drug Administration (USFDA), the company has received a warning letter from USFDA," Cipla Ltd said in a regulatory filing.

The company further said that it remains committed to maintain highest standards of compliance and will work closely with the agency to comprehensively address all the observations.

Shares of Cipla were trading at Rs 418.30 a piece on BSE in the morning trade on BSE, down 1.66 per cent from its previous close.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel